Essential GLP-1 Lab Panels — What to Test and When
The complete recommended testing protocol for GLP-1 users — from baseline labs before starting therapy through ongoing monitoring every 3–6 months. Know what improvements to expect and what values signal a need to adjust your approach.
The GLP-1 Monitoring Blueprint — Which Labs to Order and When
Before starting GLP-1 therapy (baseline): HbA1c, fasting glucose, fasting insulin, HOMA-IR (calculated), comprehensive metabolic panel (CMP — includes liver enzymes ALT/AST, kidney function creatinine/BUN, electrolytes), CBC with differential, advanced lipid panel (standard LDL/HDL/triglycerides plus LDL particle count and size via NMR LipoProfile or Cardio IQ), TSH + free T4 + free T3, vitamin D (25-OH), vitamin B12, magnesium (RBC magnesium preferred over serum), zinc, ferritin + iron panel. At 90 days: HbA1c, fasting glucose and insulin, CMP, lipid panel. At 6 months: Full baseline panel repeat. Annually: Complete repeat of all baseline markers plus uric acid, hsCRP (high-sensitivity C-reactive protein), homocysteine. Note: GLP-1 therapy commonly causes B12 reduction due to reduced dietary intake — monitor and supplement if trending low.
Glycemic Markers — HbA1c, Fasting Insulin & HOMA-IR
HbA1c (glycated hemoglobin) reflects average blood glucose over the prior 2–3 months and is the primary metric for tracking GLP-1 efficacy in pre-diabetic and type 2 diabetic patients. A reduction from 7.5% to 6.0% represents a dramatic reduction in diabetes-related complication risk. Fasting insulin (goal: below 10 mIU/L, ideally below 5) and HOMA-IR (calculated as fasting insulin × fasting glucose ÷ 405; goal below 1.5) measure insulin resistance directly — often normalizing completely after 6–12 months of GLP-1 therapy and significant weight loss. These are not always included in standard physician orders but are available on all major at-home and self-order lab platforms. Fasting insulin is arguably the single most informative marker of metabolic improvement on GLP-1 therapy.
Glycemic ControlAdvanced Lipid Panel — Beyond Standard Cholesterol
Standard lipid panels (total cholesterol, LDL, HDL, triglycerides) miss the most predictive cardiovascular risk information. Advanced lipid testing — available through Quest Diagnostics Cardio IQ panel ($89 self-pay) or LabCorp's NMR LipoProfile — measures LDL particle number (LDL-P), LDL particle size (small dense LDL is most atherogenic), HDL particle number, and VLDL subfractions. GLP-1 therapy typically shifts lipid profiles dramatically: triglycerides often drop 20–40%, LDL particle size increases toward the benign large-buoyant pattern, and HDL rises. Tracking these advanced markers over 6–12 months of GLP-1 therapy provides far more meaningful insight into cardiovascular risk reduction than standard LDL alone.
Cardiovascular RiskLiver & Kidney Function — NAFLD Resolution Monitoring
Non-alcoholic fatty liver disease (NAFLD) affects an estimated 25% of US adults and is highly prevalent in GLP-1 candidates. The comprehensive metabolic panel (CMP) includes ALT and AST liver enzymes that normalize as hepatic fat is cleared during GLP-1-induced weight loss — often within 3–6 months of therapy. GLP-1 receptor agonists have direct hepatoprotective effects beyond weight loss, with semaglutide shown in the NASH trials (ESSENCE) to resolve NASH (non-alcoholic steatohepatitis) in up to 63% of patients at 72 weeks. Kidney function markers (creatinine, BUN, eGFR) should also be monitored, as GLP-1 therapy has demonstrated nephroprotective effects in diabetic and non-diabetic patients with chronic kidney disease.
Organ HealthMicronutrient Panel — B12, D, Magnesium & Ferritin
Reduced food intake on GLP-1 therapy — even when diet quality improves — frequently leads to micronutrient insufficiency. Vitamin B12 is particularly concerning: GLP-1 users eating less animal protein and absorbing less intrinsic factor-bound B12 commonly trend toward deficiency over 12–18 months (target serum B12 above 400 pg/mL, ideally above 600). Vitamin D deficiency (below 30 ng/mL) is near-universal in obesity and may take 12+ months to correct even with supplementation. Magnesium deficiency (RBC magnesium below 5.2 mg/dL) impairs insulin sensitivity and sleep quality. Ferritin below 30 ng/mL indicates iron depletion even when serum iron appears normal, and is common in women on GLP-1 therapy with reduced red meat intake.
MicronutrientsWhat Improvements to Expect — the GLP-1 Lab Transformation Timeline
Understanding what your labs should show — and when — helps you recognize whether your GLP-1 therapy is working optimally and whether any adjustments are needed.
- 30–90 days: Fasting glucose drops, HbA1c begins falling, triglycerides improve significantly, ALT/AST start normalizing if elevated at baseline
- 3–6 months: HbA1c reaches target in most pre-diabetic patients, fasting insulin falls substantially, LDL particle size shifts favorable, vitamin D improving with supplementation
- 6–12 months: HOMA-IR may normalize completely, advanced lipids fully transformed, eGFR stable or improved, thyroid function stable (GLP-1 does not affect thyroid in humans at therapeutic doses)